

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)



(10) International Publication Number
WO 2022/204438 A1

(51) International Patent Classification:

C12Q 1/6886 (2018.01) A61K 31/00 (2006.01)
G16B 20/00 (2019.01) A61K 39/00 (2006.01)

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2022/021806

(22) International Filing Date:

24 March 2022 (24.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/166,167 25 March 2021 (25.03.2021) US
63/188,321 13 May 2021 (13.05.2021) US

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(71) Applicant: ONCXERNA THERAPEUTICS, INC.

[US/US]; 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US).

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(72) Inventors: BENJAMIN, Laura E.; c/o OncXerna Therapeutics, Inc., 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US). STRAND-TIBBITTS, Kristen; c/o OncXerna Therapeutics, Inc., 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US). ROSEN-GARTEN, Rafael; c/o OncXerna Therapeutics, Inc., 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US). ŠTAJDOHAR, Miha; c/o OncXerna Therapeutics, Inc., 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US). CVITKOVIČ, Robert; c/o OncXerna Therapeutics, Inc., 300 Fifth Avenue, Suite 6040, Waltham, Massachusetts 02451 (US).

(74) Agent: FRUEAUF, Jeremiah, B. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,

(54) Title: TARGETED THERAPIES IN CANCER

(57) Abstract: The disclosure provides methods to categorize cancers and cancer patients using a classifier, TME Panel-1, which stratifies patients and cancers according to tumor microenvironments. Treatment decisions are then guided by the presence/absence of a particular TME phenotype class. Also provided are methods for treating a subject, e.g., a human subject, afflicted with gastric cancer, breast cancer, prostate cancer, liver cancer, carcinoma of head and neck, melanoma, colorectal cancer, or ovarian cancer comprising administering a particular therapy depending on the classification of the cancer's TME according to the TME Panel-1 classifier. Also provided are personalized treatments that can be administered to patients depending on the TME Panel-1 classification of a particular type of cancer, e.g., left or right colorectal cancer or dMMR colorectal cancer.



WO 2022/204438 A1